NR2F6 Ligand Binding Assay for Compound Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively identifying and screening compounds that act as agonists or antagonists of the orphan nuclear receptor NR2F6, which plays a crucial role in various biological processes including cancer cell proliferation and differentiation.
Innovation Solution
A method involving the expression of recombinant DNA vectors to generate proteins for a ligand binding assay, using a known ligand to measure the binding affinity of test compounds to NR2F6, employing techniques such as fluorescence polarization or radiolabeling to determine the ability of test compounds to occupy the active site of NR2F6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional screening methods are used to identify NR2F6 modulators, then the screening process is simple, but the ability to effectively identify agonists and antagonists is inadequate
Solution Approach 1:
The patent uses a labeled reference ligand as an intermediary to indirectly measure test compound binding to NR2F6. The reference ligand competes with test compounds for the NR2F6 binding site, and its labeled status enables detection of displacement events, thereby improving identification accuracy without requiring direct labeling of the receptor
Solution Approach 2:
The patent replaces conventional direct binding assays with a competitive binding assay system that uses fluorescence polarization or radiometric detection. This substitution enables more precise measurement of binding affinity through optical or radioactive signals rather than direct mechanical or chemical measurement of receptor-ligand interactions
2Measurement precision
If a ligand binding assay system is developed to measure test compound binding to NR2F6, then the identification accuracy of modulators is improved, but the assay development complexity increases
Solution Approach 1:
The patent performs preliminary actions by selecting and characterizing a reference ligand that binds to NR2F6 before developing the screening assay. This reference ligand is pre-labeled with a detectable marker, and its binding parameters are established in advance, which simplifies subsequent assay development and standardization
Solution Approach 2:
The patent employs parameter changes by utilizing labeled reference ligands with different labels (radioactive or fluorescent) and optimizing assay conditions such as buffer composition, temperature, and incubation time. These parameter adjustments enable the assay to achieve high measurement precision while maintaining ease of implementation through systematic optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of compounds that modulate NR2F6 activity, potentially leading to treatments for diseases related to cancer and other disorders by determining the binding affinity and specificity of test compounds to NR2F6, thereby influencing its functional regulation.
Implementation Method 1
employing techniques such as fluorescence polarization or radiolabeling to determine the ability of test compounds to occupy the active site of NR2F6
Implementation Method 2
Labeling the known ligand using radioactive or non-radioactive methods
Data Source
AI summary
The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound.